a public good project by the
Synthesis
Company
of California

© 2026

Martin J. Drysdale | doi.page

0 works0 citations0 h-index

Martin J. Drysdale

GlaxoSmithKline (United Kingdom)(GB)Cancer Research UK Scotland Institute(GB)

Publications by Year

Research Areas

Heat shock proteins research, Computational Drug Discovery Methods, Enzyme Structure and Function, Endoplasmic Reticulum Stress and Disease, Cyclopropane Reaction Mechanisms

Most-Cited Works

→ NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis(2008)476 cited
→ 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer(2007)442 cited
→ A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells(2009)327 cited
→ Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms(2004)266 cited
→ Novel, Potent Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based Design(2005)231 cited
→ NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models(2008)222 cited

→ Novel Adenosine-Derived Inhibitors of 70 kDa Heat Shock Protein, Discovered Through Structure-Based Design(2009)222 cited

→ Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone(2009)173 cited

→ Fragment-based hit identification: thinking in 3D(2013)155 cited

→ Rational Design of Inhibitors of HIV-1 TAR RNA through the Stabilisation of Electrostatic “Hot Spots”(2004)155 cited